SFPIA
ESPR

Stevens First Principles Investment Advisors’s Esperion Therapeutics ESPR Stock Holding History

Stevens First Principles Investment Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-200
Closed -$4K – 155
2015
Q4 		$4K Buy
+200
New +$5.05K ﹤0.01% 165

Other funds holding ESPR

AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

Stevens First Principles Investment Advisors's ESPR Position: Q1 2016 in Review

Stevens First Principles Investment Advisors sold out of Esperion Therapeutics (ESPR) in Q1 2016, closing a stake of 200 shares — an estimated $4K sold.

Stevens First Principles Investment Advisors first reported a position in ESPR in Q4 2015 and held it in 1 quarter. The position peaked at $4K in Q4 2015. 109 funds tracked by Wall St. Rank hold ESPR as of Q1 2016.

  • Stevens First Principles Investment Advisors reported no remaining Esperion Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Stevens First Principles Investment Advisors sold 200 Esperion Therapeutics shares in Q1 2016, an estimated $4K.
  • Stevens First Principles Investment Advisors first reported a position in Esperion Therapeutics in Q4 2015 and held it in 1 quarter.
  • Stevens First Principles Investment Advisors's Esperion Therapeutics position peaked at $4K in Q4 2015.
  • 109 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2016.

Based on Stevens First Principles Investment Advisors's 13F filing for Q1 2016, filed 13 May 2016.